A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT06996782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT06996782
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 152 participants
Conditions and interventions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Nab-paclitaxel Drug
- Paclitaxel Drug
- Pemetrexed Drug
- Ramucirumab Drug
- Rilvegostomig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 23, 2025
- Primary completion
- Feb 22, 2029
- Completion
- Feb 22, 2029
- Last update posted
- Apr 30, 2026
2025 – 2029
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | Recruiting |
| Research Site | Santa Rosa | California | 95403 | Recruiting |
| Research Site | Jacksonville | Florida | 32224 | Recruiting |
| Research Site | Baltimore | Maryland | 21201 | Not yet recruiting |
| Research Site | Detroit | Michigan | 48202 | Not yet recruiting |
| Research Site | Rochester | Minnesota | 55905 | Recruiting |
| Research Site | Cleveland | Ohio | 44106 | Recruiting |
| Research Site | Providence | Rhode Island | 02903 | Recruiting |
| Research Site | Providence | Rhode Island | 02906 | Withdrawn |
| Research Site | Tyler | Texas | 75708 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06996782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06996782 live on ClinicalTrials.gov.